Koers MabVax Therapeutics Holdings, Inc.
Aandelen
MBVXQ
US55414P7024
Biotechnologie & Medisch Onderzoek
Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
- USD | -.--% |
|
+10,05% | +182,21% |
Omzet 2016 | 148K 137K | Omzet 2017 | - | Marktkapitalisatie | 14,41 mln. 13,3 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2016 | -17 mln. -15,68 mln. | Nettowinst (verlies) 2017 | -19 mln. -17,53 mln. | EV/omzet 2016 | 147 x |
Nettoschuld 2016 | 470K 434K | Nettoschuld 2017 | 2,48 mln. 2,29 mln. | EV/omzet 2017 | - |
K/w-verhouding 2016 |
-0,93
x | K/w-verhouding 2017 |
-0,25
x | Werknemers | - |
Dividendrendement 2016 * |
-
| Dividendrendement 2017 |
-
| Vrij verhandelbaar | 92,02% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 72 | - | |
Chief Tech/Sci/R&D Officer | 81 | 08-07-14 | |
Paul W. Maffuid
CTO | Chief Tech/Sci/R&D Officer | 68 | 08-07-14 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chief Tech/Sci/R&D Officer | 81 | 08-07-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+182,21% | 213K | |
+20,82% | 127 mld. | |
+21,96% | 116 mld. | |
+24,25% | 27,69 mld. | |
-22,97% | 19,62 mld. | |
-17,05% | 16,26 mld. | |
-19,03% | 15,49 mld. | |
+11,66% | 14,81 mld. | |
-48,41% | 14,39 mld. | |
+54,78% | 14,11 mld. |